{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:53Z","timestamp":1780639493693,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Differences in bleeding risk among direct oral anticoagulants (DOACs) may reflect not only exposure-related factors but also molecule-specific drug\u2013target interaction characteristics. This study aimed to evaluate real-world bleeding outcomes and to complement these findings with molecular docking analyses as supportive, hypothesis-generating mechanistic context for safety differences among factor Xa inhibitors and a direct thrombin inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of 5,721 patients treated with apixaban, rivaroxaban, edoxaban, or dabigatran was analyzed using real-world clinical data. Demographic characteristics, comorbidities, non\u2013life-threatening complications, life-threatening hemorrhagic events, and overall bleeding outcomes were systematically compared. Multivariable logistic regression modeling was used to identify independent predictors of bleeding, with apixaban as the reference agent. Molecular docking analyses were performed using AutoDock 4.2.6 to assess comparative binding energy profiles, hydrogen bond interactions, and root-mean-square deviation values between each DOAC and factor Xa or thrombin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Life-threatening bleeding occurred in 3.1% of patients, while any bleeding event was observed in 13.5% of the cohort. Compared with apixaban, rivaroxaban (OR 1.52), dabigatran (OR 1.29), and edoxaban (OR 1.44) were independently associated with higher odds of bleeding. Advanced age and renal dysfunction were identified as additional independent predictors. Docking analyses indicated that apixaban exhibited the lowest docking-derived binding energy toward factor Xa (\u0394G = \u221214.46\u00a0kcal\/mol), whereas dabigatran showed selective interaction with thrombin (\u0394G = \u221211.91\u00a0kcal\/mol). These molecular findings are exploratory and hypothesis-generating and should be interpreted as supportive mechanistic context rather than direct predictors of clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective cohort, apixaban was associated with a comparatively lower observed bleeding risk compared with other DOAC agents. Docking findings provide exploratory, hypothesis-generating mechanistic context that may help to contextualize observed clinical patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1828307","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:41Z","timestamp":1780638041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and in silico docking"],"prefix":"10.3389","volume":"17","author":[{"given":"Lutfi Cagatay","family":"Onar","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Dr. Ismail Fehmi Cumalioglu City Hospital, Ministry of Health, Republic of Turkey","place":["Tekirdag, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersin","family":"Guner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Konya Numune Hospital, Ministry of Health, Republic of Turkey","place":["Konya, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Unit of Pharmacovigilance, Dr. Ismail Fehmi Cumalioglu City Hospital, Ministry of Health, Republic of Turkey","place":["Tekirdag, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1049283","DOI":"10.3389\/fphar.2022.1049283","article-title":"Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: an updated traditional and Bayesian network meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/jth.15642","article-title":"Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity","volume":"20","author":"D\u00f3lleman","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/nejmoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/bcp.15582","article-title":"Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study","volume":"89","author":"Grymonprez","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10557-023-07507-3","article-title":"Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death: a nationwide cohort study","volume":"39","author":"Grymonprez","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/(sici)1096-987x(199604)17:5\/6<490::aid-jcc1>3.0.co;2-p","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J. Comput. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B12","volume-title":"IBM SPSS Statistics for Windows, Version 25.0","year":"2017"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.3390\/ijms25168727","article-title":"Beyond anticoagulation: a comprehensive review of non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling","volume":"25","author":"Jannati","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1399955","DOI":"10.3389\/fphar.2024.1399955","article-title":"Exploring bleeding in oral anticoagulant users: assessing incidence by indications and risk factors in the entire nationwide cohort","volume":"15","author":"Jeong","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/phar.70055","article-title":"Restarting oral anticoagulation in patients with atrial fibrillation after admission for gastrointestinal bleeding: effectiveness and safety of direct oral anticoagulants compared with warfarin","volume":"45","author":"Lawal","year":"2025","journal-title":"Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0310322","DOI":"10.1371\/journal.pone.0310322","article-title":"Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: a nationwide French cohort study","volume":"19","author":"Lip","year":"2024","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2547678","DOI":"10.1080\/20523211.2025.2547678","article-title":"A real-world safety evaluation of new oral anticoagulants in elderly patients: evidence from the adverse drug reaction monitoring center of Henan Province","volume":"18","author":"Ma","year":"2025","journal-title":"J. Pharm. Policy Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0310883","DOI":"10.1371\/journal.pone.0310883","article-title":"Modelling the effects of four-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding","volume":"19","author":"Muir","year":"2024","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Cheminform"},{"key":"B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","article-title":"Discovery of apixaban, a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa","volume":"50","author":"Pinto","year":"2007","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3390\/jcm13092451","article-title":"Coagulation tests and reversal agents in patients treated with oral anticoagulants: the challenging scenarios of life-threatening bleeding and unplanned invasive procedures","volume":"13","author":"Pozzi","year":"2024","journal-title":"J. Clin. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1080\/14740338.2024.2368815","article-title":"Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database","volume":"23","author":"Qian","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of rivaroxaban, an oral direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J. Med. Chem."},{"key":"B28","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"17","author":"Sanner","year":"1999","journal-title":"J. Mol. Graph Model"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1007\/s00520-022-07433-4","article-title":"Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis","volume":"30","author":"Wu","year":"2022","journal-title":"Support Care Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1828307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:42Z","timestamp":1780638042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1828307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":30,"alternative-id":["10.3389\/fphar.2026.1828307"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1828307","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1828307"}}